アブストラクト
Japanese
| Title | アトピー性皮膚炎の機序とJAK阻害外用薬 (デルゴシチニブ) の有用性 |
|---|---|
| Subtitle | 解説 : 免疫アレルギー疾患における分子標的薬 |
| Authors | 梶田直樹, 吉田幸一 |
| Authors (kana) | |
| Organization | 東京都立小児総合医療センターアレルギー科 |
| Journal | 日本小児アレルギー学会誌 |
| Volume | 37 |
| Number | 5 |
| Page | 513-518 |
| Year/Month | 2023 / |
| Article | 報告 |
| Publisher | 日本小児アレルギー学会 |
| Abstract | 「抄録」 : アトピー性皮膚炎の炎症に関わる多くのサイトカインのシグナル伝達において, JAK/STAT経路が関与する. 近年, 本邦から発売されたデルゴシチニブは, JAKファミリーのすべてのキナーゼ活性を阻害する外用剤であり, Th2サイトカインを始めとしたアトピー性皮膚炎の炎症に関わる種々のサイトカインを抑制することで治療効果を得る. 小児を対象としたデルゴシチニブの第II層, 第III層臨床試験ではアトピー性皮膚炎の重症度の改善や痒みの改善効果がみられており, ステロイド外用薬やタクロリムス軟膏以外の新たなアトピー性皮膚炎の外用治療薬の選択肢の一つとして期待される. 本稿では, アトピー性皮膚炎の病態におけるサイトカインの分子機序を併せて, デルゴシチニブについて解説する. |
| Practice | 臨床医学：内科系 |
| Keywords | JAK/STAT経路, デルゴシチニブ, 2型サイトカイン, 分子標的薬, ヤヌスキナーゼ阻害薬, delgocitinib, JAK inhbitor, JAK/STAT pathway, molecularly targeted drug, type 2 cytokine |
English
| Title | Mechanism of atopic dermatitis and usefulness of topical JAK inhibitor (delgocitinib) |
|---|---|
| Subtitle | |
| Authors | Naoki Kajita, Koichi Yoshida |
| Authors (kana) | |
| Organization | Department of Allergy, Tokyo Metropolitan Children's Medical Center |
| Journal | The Japanese Journal of Pediatric Allergy and Clinical Immunology |
| Volume | 37 |
| Number | 5 |
| Page | 513-518 |
| Year/Month | 2023 / |
| Article | Report |
| Publisher | Japanese Society of Pediatric Allergy and Clinical Immunology |
| Abstract | [Summary :] The JAK/STAT pathway has a role in the signal transduction of many cytokines involved in inflammation in atopic dermatitis. Delgocitinib, which was recently released in Japan, is a topical agent that inhibits the activity of all JAK family kinases and achieves its therapeutic effect by suppressing various cytokines involved in inflammation in atopic dermatitis. Phase 2 and 3 clinical trials of delgocitinib ointment in children found that the drug decreased the severity of atopic dermatitis and reduced the itching score. It may therefore take its place among topical steroids and tacrolimus ointment as a new topical agent for atopic dermatitis. The present article describes the molecular mechanism of cytokines in the pathogenesis of atopic dermatitis and the pharmacological activity of delgocitinib ointment against the disease. |
| Practice | Clinical internal medicine |
| Keywords | delgocitinib, JAK inhbitor, JAK/STAT pathway, molecularly targeted drug, type 2 cytokine |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 佐藤秀久, 他. アトピー性皮膚炎診療ガイドライン 2021. 日本皮膚科学会雑誌 2021 ; 131 : 2691-2777.
- 2) O'Regan GM, et al. Filaggrin in atopic dermatitis. J Allergy Clin Immunol 2008 ; 122 : 689-693.
- 3) Thyssen JP, Kezic S. Causes of epidermal filag-grin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 2014 ; 134 : 792-799.
- 4) Datsi A, et al. Interleukin-31: The "itchy" cytokine in inflammation and therapy. Allergy Eur J Al-lergy Clin Immunol 2021 ; 76 : 2982-2997.
- 5) Wilson SR, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to in-duce itch. Cell 2013 ; 155 : 285-295.
残りの15件を表示する
- 6) Trier AM, et al. IL-33 signaling in sensory neu-rons promotes dry skin itch. J Allergy Clin Immu-nol 2022 ; 149 : 1473-1480. e6.
- 7) Nakajima S, et al. Anti-TSLP antibodies: Target-ing a master regulator of type 2 immune re-sponses. Allergol Int 2020 ; 69 : 197-203.
- 8) Shiraishi H, et al. Periostin contributes to the pathogenesis of atopic dermatitis by inducing TSLP production from keratinocytes. Allergol Int 2012 ; 61 : 563-572.
- 9) Kamata M, Tada Y. Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence. JID Innov 2023 ; 3 : 100195.
- 10) Schwartz DM, et al. JAK inhibition as a therapeu-tic strategy for immune and inflammatory dis-eases. Nat Rev Drug Discov 2017 ; 16 : 843-862.
- 11) Tanimoto A, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that sup-presses various inflammatory responses in vitro and in vivo. Inflamm Res 2015 ; 64 : 41-51.
- 12) Tanimoto A, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. Exp Der-matol 2018 ; 27 : 22-29.
- 13) Nakagawa H, et al. Phase 2 clinical study of delgo-citinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol 2019 ; 144 : 1575-1583.
- 14) Nakagawa H, et al. Delgocitinib ointment in pedi-atric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol 2021 ; 85 : 854-862.
- 15) Nakagawa H, et al. Safety, efficacy, and pharma-cokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study. Allergol Int 2023. https://doi.org/10.1016/j.alit.2023.04.003
- 16) Sadeghi S, Mohandesi NA. Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review. Exp Dermatol 2023 ; 32 : 599-610.
- 17) Alves C, et al. Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis. Int J Clin Pharm 2023 ; 45 : 830-838.
- 18) Guttman-Yassky E, et al. Efficacy and safety of fezakinumab(an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treat-ments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol 2018 ; 78 : 872-881. e6.
- 19) Tsoi LC, et al. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Allergy Clin Immunol 2022 ; 149 : 1329-1339.
- 20) Nakashima C, Yanagihara S, Otsuka A. Innova-tion in the treatment of atopic dermatitis: Emerg-ing topical and oral Janus kinase inhibitors. Aller-gol Int 2022 ; 71 : 40-46.
